Argenica Therapeutics (ASX:AGN) Pretax Margin %: % (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
30 GF Score
Price A$0.14
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Pretax Margin %?

Argenica Therapeutics ASX:AGN +12.00% 30 Pretax Margin % is % as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Argenica Therapeutics ranks worse than 106269.82% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Argenica Therapeutics's Pre-Tax Income for the six months ended in Dec. 2025 was A$-3.82 Mil. Argenica Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Argenica Therapeutics's pretax margin for the quarter that ended in Dec. 2025 was %.

The historical rank and industry rank for Argenica Therapeutics's Pretax Margin % or its related term are showing as below:


ASX:AGN's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

Argenica Therapeutics  (ASX:AGN) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Argenica Therapeutics Pretax Margin % Related Terms

Argenica Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Pretax Margin % Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Pretax Margin %
0.00 0.00 0.00 0.00 0.00

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:AGN vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Argenica Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argenica Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Pretax Margin % falls into.


ASX:AGN
30GF Score
Argenica Therapeutics Ltd ASX:AGN
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Argenica Therapeutics's Pretax Margin for the fiscal year that ended in Jun. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.17/0
= %

Argenica Therapeutics's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.817/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Argenica Therapeutics (ASX:AGN) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Argenica Therapeutics and its competitors. According to the industry distribution chart, Argenica Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is Argenica Therapeutics' Pretax Margin % too high?
Argenica Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Argenica Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Argenica Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Argenica Therapeutics ranks #999999 out of 941 companies for Pretax Margin %. This places Argenica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Pretax Margin % of %. The current Pretax Margin % is %. Argenica Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
30GF Score

Get the complete analysis for ASX:AGN

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price